RxDoctor Payments Data

Margo Klingensmith

Physician Assistant · Naples, FLNPI 1831443530

Payments from drug & device makers

$4,918in general payments, 2019–2025

Across 229 payments — averaging $21.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$749
  • Novo Nordisk$678
  • Sumitomo Pharma America, Inc.$479
  • AstraZeneca$383
  • Amgen$378
  • Lilly USA, LLC$309
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,918 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$110,733
Medicare patients
639
Services billed
3,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$35,618
EliquisApixaban22$29,372
MounjaroTirzepatide15$23,722
FarxigaDapagliflozin Propanediol20$16,837
Breo ElliptaFluticasone/Vilanterol14$6,238
Rosuvastatin Calcium74$1,322
Albuterol Sulfate HfaAlbuterol Sulfate62$1,100
Atorvastatin Calcium86$928
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst91$892
Metoprolol Succinate65$890
Amlodipine Besylate111$813
Losartan Potassium80$792
Valsartan17$737
Levothyroxine Sodium75$711
Escitalopram Oxalate61$612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$678$35,61829 claims
PfizerEliquis$749$29,37222 claims
Lilly USA, LLCMounjaro$309$23,72215 claims
AstraZenecaFarxiga$383$16,83720 claims
GSKBreo Ellipta$64$6,23814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →